



(12) Translation of
European patent specification

(11) NO/EP 2332947 B1

NORWAY

(19) NO
(51) Int Cl.
C07H 15/14 (2006.01)
A61K 31/70 (2006.01)
A61P 3/10 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2018.03.19
(80)	Date of The European Patent Office Publication of the Granted Patent	2017.11.01
(86)	European Application Nr.	11155100.8
(86)	European Filing Date	2009.07.15
(87)	The European Application's Publication Date	2011.06.15
(30)	Priority	2008.07.17, US, 81423 P
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Lexicon Pharmaceuticals, Inc., 8800 Technology Forest Place, The Woodlands, TX 77381-1160, US-USA
(72)	Inventor	De Paul, Susan Margaret, Berninastrasse 11, CH-8057, Zurich, CH-Sveits Perlberg, Anett, Niederhofweg 11, CH-4617, Gunzgen, CH-Sveits Zhao, Matthew Mangzhu, 1 Whittier Street, Edison, NJ NJ 08820, US-USA
(74)	Agent or Attorney	HÅMSØ PATENTBYRÅ AS, Postboks 171, 4301 SANDNES, Norge

(54)	Title	SOLID FORMS OF (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL AND METHODS OF THEIR USE
(56)	References Cited:	BYRN S R ET AL: "Solid-State Chemistry of Drugs", 1 January 1999 (1999-01-01), SOLID-STATE CHEMISTRY OF DRUGS, SSCI INC, WEST LAFAYETTE, PAGE(S) 82 - 85, XP002588305, ISBN: 978-0-9670671-0-0 * page 84 *, WO-A-2008/042688

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

P a t e n t k r a v

1. En farmasøytisk sammensetning som omfatter krystallinsk vannfri (2S,3R,4R,5S,6R)-2-(4-kloro-3-(4-etoksybenzyl)fenyl)-6-(metyltio)tetrahydro-2H-pyran-3,4,5-triol, hvori det krystallinske vannfrie (2S,3R,4R,5S,6R)-2-(4-kloro-3-(4-etoksybenzyl)fenyl)-6-(metyltio)tetrahydro-2H-pyran-3,4,5-triol har en DSC endoterm på $124^{\circ}\text{C} \pm 5.0^{\circ}\text{C}$ eller $134^{\circ}\text{C} \pm 5.0^{\circ}\text{C}$.
2. En farmasøytisk doseringsform som omfatter en aktiv farmasøytisk bestanddel og et farmasøytisk akseptabelt hjelpestoff, hvori den aktive farmasøytiske bestanddelen er krystallinsk vannfri (2S,3R,4R,5S,6R)-2-(4-kloro-3-(4-etoksybenzyl)fenyl)-6-(metyltio)tetrahydro-2H-pyran-3,4,5-triol, hvori det krystallinske vannfrie (2S,3R,4R,5S,6R)-2-(4-kloro-3-(4-etoksybenzyl)fenyl)-6-(metyltio)tetrahydro-2H-pyran-3,4,5-triol har en DSC endoterm på $124^{\circ}\text{C} \pm 5.0^{\circ}\text{C}$ eller $134^{\circ}\text{C} \pm 5.0^{\circ}\text{C}$.
3. Den farmasøytiske doseringsformen av krav 2, som er en tablett, kapsel eller kaplett.
4. Krystallinsk vannfri (2S,3R,4R,5S,6R)-2-(4-kloro-3-(4-etoksybenzyl)fenyl)-6-(metyltio)tetrahydro-2H-pyran-3,4,5-triol for bruk til å behandle eller håndtere aterosklerosis, kardiovaskulær sykdom, diabetes (type 1 eller 2), hyperglykemi, hypertensjon, lipidelser, fedme, eller syndrom X, hvori det krystallinske vannfrie (2S,3R,4R,5S,6R)-2-(4-kloro-3-(4-etoksybenzyl)fenyl)-6-(metyltio)tetrahydro-2H-pyran-3,4,5-triol har en DSC endoterm på $124^{\circ}\text{C} \pm 5.0^{\circ}\text{C}$ eller $134^{\circ}\text{C} \pm 5.0^{\circ}\text{C}$.
5. Krystallinsk vannfri (2S,3R,4R,5S,6R)-2-(4-kloro-3-(4-etoksybenzyl)fenyl)-6-(metyltio)tetrahydro-2H-pyran-3,4,5-triol for bruk i fremstillingen av et medikament for å behandle eller håndtere aterosklerosis, kardiovaskulær sykdom, diabetes (type 1 eller 2), hyperglykemi, hypertensjon, lipidelser, fedme, eller syndrom X, hvori det krystallinske vannfrie (2S,3R,4R,5S,6R)-2-(4-kloro-3-(4-etoksybenzyl)fenyl)-6-(metyltio)tetrahydro-2H-pyran-3,4,5-triol har en DSC endoterm på $124^{\circ}\text{C} \pm 5.0^{\circ}\text{C}$ eller $134^{\circ}\text{C} \pm 5.0^{\circ}\text{C}$.
6. Forbindelsen for bruk av krav 4 eller 5, hvori sykdommen eller lidelsen er diabetes.